Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/7/2025 | $30.00 | Sector Outperform | Scotiabank |
| 2/10/2025 | $40.00 | Outperform | Oppenheimer |
| 8/20/2024 | Overweight | Cantor Fitzgerald | |
| 8/13/2024 | $18.00 → $22.00 | Outperform → Strong Buy | Raymond James |
| 8/12/2024 | $19.00 → $20.00 | Outperform | Leerink Partners |
| 7/25/2024 | $18.00 | Outperform | Raymond James |
| 3/5/2024 | $6.00 → $18.00 | Market Perform → Outperform | Leerink Partners |
| 2/20/2024 | Mkt Perform → Outperform | William Blair |
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), expanding the reach of neffy to approximately 2 million younger, school-aged children at risk of a severe allergic reaction $314.0 million in cash, cash equivalents, and short-term investments at year-end 2024, supporting an increased investment in commercialization in 2025 while maintaining an operating runway of at least three years Company to host conference call today, March 20, 2025 at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March
neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that the U.S. Food and Drug Administration (FDA) has approved neffy® 1 mg (epinephrine nasal spray) for the treatment of Type I Allergic Reactions, including anaphylaxis, in children who are aged 4 years and older and weigh 15 to < 30 kilograms (33 to < 66 lb.). This approval represents the first significant innovation in the
Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, March 20, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results and business highlights. The dial-in information for conference participants may be obtained by registering for the event. In addition, ARS Pharma Management will be participating in several upcoming
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), expanding the reach of neffy to approximately 2 million younger, school-aged children at risk of a severe allergic reaction $314.0 million in cash, cash equivalents, and short-term investments at year-end 2024, supporting an increased investment in commercialization in 2025 while maintaining an operating runway of at least three years Company to host conference call today, March 20, 2025 at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March
Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, March 20, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results and business highlights. The dial-in information for conference participants may be obtained by registering for the event. In addition, ARS Pharma Management will be participating in several upcoming
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (("ARS Pharma", NASDAQ:SPRY). The agreement grants ALK exclusive global rights to the neffy® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK's new strategy Allergy+ and supports ALK's long-term financial ambitions. Needle-free, nasal delivery of adrenaline has the potential to become an important treatment option in anaphylaxisALK also gains rights to future indications, including acute urticaria flares (in development)ALK to pay USD 145 million in up
SCHEDULE 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
S-8 - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
10-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
Scotiabank initiated coverage of ARS Pharmaceuticals with a rating of Sector Outperform and set a new price target of $30.00
Oppenheimer initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $40.00
Cantor Fitzgerald initiated coverage of ARS Pharmaceuticals with a rating of Overweight
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured